报价延迟最少15分钟:2025/11/16 04:41 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.71 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.26/-0.67
|
|
企业价值
125.22M
|
| 资产负债 |
|
每股账面净值
0.38
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
365.00K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 04:41 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles. |
